Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 24 July
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued:
Tuesday 24 July 2018, London UK - LSE Announcement
ViiV Healthcare presents phase III data at AIDS 2018 from landmark
GEMINI studies showing two-drug regimen of dolutegravir and
lamivudine has similar efficacy to a three-drug regimen in
treatment naïve HIV patients, with no emergence of
resistance.
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug
regimen to be effective across high and low viral
loads.
London,
24 July 2018
ViiV
Healthcare today presented at the 22nd International AIDS
conference in Amsterdam 48-week results from the phase III
GEMINI 1 & 2 studies, assessing the safety and efficacy of a
two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)
compared to a three-drug regimen of dolutegravir and two nucleoside
reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil
fumarate/emtricitabine (TDF/FTC), in treatment naïve HIV-1
infected adults with baseline viral loads
up to 500,000 copies per millilitre (c/mL).
The
studies met their primary endpoint for non-inferiority based on
plasma HIV-1 RNA <50c/mL, a standard measure of HIV control, at
Week 48. In a pooled analysis, 91% (655/716) of patients taking DTG
+ 3TC had HIV-1 RNA<50 copies/mL compared with 93% (669/717) of
patients taking DTG +TDF/FTC [adjusted difference -1.7% (95% CI:
-4.4%, 1.1%)].
Pedro
Cahn, principal investigator for the GEMINI study programme said:
"For the last 15-20 years, the standard of care for HIV has
revolved around three-drug regimens. Now that we have more potent
drugs, the focus is shifting to tolerability and convenience. The
GEMINI studies show that we can get the efficacy of three drugs in
a two-drug regimen with the tolerability and drug interaction
profile of DTG and 3TC. These are important findings for people
living with HIV who will spend their lifetime taking drugs to
suppress their virus. The studies have the potential to expand the
treatment paradigm for first-line therapy of people living with
HIV."
Results
show broadly consistent results for virus suppression across
individuals with higher viral load (more than 100,000 copies of
viral RNA per millilitre of blood plasma [>100,000c/mL]) and
lower viral load (<=100,000 c/mL) HIV-1 plasma RNA. Rates of
virologic failure were ≤1% across all arms of the study. No
patient who experienced virologic failure in either treatment arm
developed treatment-emergent resistance.
The
percentage of patients that withdrew due to adverse events was 2%
in each study arm (GEMINI I DTG + 3TC arm: n=7, GEMINI I DTG +
TDF/FTC arm n=8, GEMINI II DTG + 3TC arm = 8, GEMINI II DTG +
TDF/FTC arm n = 8). Pooled results show that the most common
(≥5%) adverse events across the studies were headache,
diarrhoea and nasopharyngitis in both arms (DTG + 3TC arm: 10%, 9%,
and 8%, respectively, DTG + TDF/FTC: 10%, 11%, and 11%,
respectively).
Drug-related
adverse events were less frequent in patients on the DTG/3TC
regimen (126/716, 18%), compared with those on the DTG + TDF/FTC
regimen (169/717, 24%).
John C.
Pottage, Jr., MD, Chief Scientific and Medical Officer of ViiV
Healthcare, said: "These data we have presented at AIDS 2018
provide further evidence that we should be rethinking the
traditional approach to HIV treatment of using three or more drugs.
The results from the GEMINI programme support our belief that the
two-drug regimen of dolutegravir and lamivudine can be a valuable
option for treatment-naïve patients and that no patient should
take more medicine than they need."
ViiV
Healthcare intends to seek regulatory approval for a
fixed-dose combination of DTG and 3TC later this year. DTG and 3TC,
as a 2DR, is not yet approved for use by the US FDA.
Notes
to editors
GEMINI
1 & 2 study design
The
GEMINI studies are part of ViiV Healthcare's innovative clinical
trial programme, which seeks to increase the body of evidence
supporting the use of two-drug regimens for the treatment of HIV,
in order to ensure that no patient is taking more medication than
they need. The GEMINI studies are ongoing for 148
weeks.
GEMINI
1 (204861) and GEMINI 2 (205543) are duplicate, phase III,
randomised, double-blind, multicentre, parallel group,
non-inferiority studies. These studies evaluate a two-drug regimen
of dolutegravir and lamivudine compared with a three-drug,
first-line regimen of DTG + TDF/FTC in HIV-1 infected,
antiretroviral therapy (ART)-naïve adult participants with
baseline HIV-1 viral loads up to 500,000 copies per ml. The studies
are designed to demonstrate the non-inferior efficacy, safety, and
tolerability of once-daily dolutegravir and lamivudine compared to
once-daily dolutegravir and the fixed-dose combination of TDF/FDC
at 48 weeks in HIV-1-infected, ART-naïve
participants.
For
more information please search for NCT02831673 (GEMINI 1) or
NCT02831764 (GEMINI 2) on www.clinicaltrials.gov.
U.S
INDICATIONS AND IMPORTANT SAFETY INFORMATION
About
Tivicay® (dolutegravir)
Dolutegravir
(Tivicay) is an integrase strand transfer inhibitor (INSTI) for use
in combination with other antiretroviral agents for the treatment
of HIV. Integrase inhibitors block HIV replication by preventing
the viral DNA from integrating into the genetic material of human
immune cells (T-cells). This step is essential in the HIV
replication cycle and is also responsible for establishing chronic
infection. Tivicay is approved in over 100 countries across North
America, Europe, Asia, Australia, Africa and Latin
America.
TIVICAY (dolutegravir tablets
Professional Indication(s) and Important Safety Information
U.S.
Indications and Usage
TIVICAY
is a human immunodeficiency virus type 1 (HIV-1) integrase strand
transfer inhibitor (INSTI) indicated in combination
with:
● other
antiretroviral agents for the treatment of HIV-1 infection in
adults and pediatric patients weighing at least 30 kg
● rilpivirine
as a complete regimen for the treatment of HIV-1 infection in
adults to replace the current antiretroviral regimen in those who
are virologically suppressed (HIV-1 RNA < 50 copies per mL) on a
stable antiretroviral regimen for ≥6 months with no history
of treatment failure or known substitutions associated with
resistance to either antiretroviral agent.
Important
safety information: Tivicay (dolutegravir)
The
following ISI is based on the Highlights section of the Prescribing
Information for Tivicay. Please consult the full Prescribing
Information for all the labelled safety information for
Tivicay.
Contraindications
●
Previous hypersensitivity reaction to dolutegravir.
●
Coadministration with dofetilide.
Warnings
and precautions
● Hypersensitivity
reactions characterized by rash, constitutional findings, and
sometimes organ dysfunction, including liver injury, have been
reported. Discontinue TIVICAY and other suspect agents immediately
if signs or symptoms of hypersensitivity reactions develop, as a
delay in stopping treatment may result in a life-threatening
reaction.
● Hepatotoxicity
has been reported in patients receiving dolutegravir-containing
regimens. Patients with underlying hepatitis B or C may be at
increased risk for worsening or development of transaminase
elevations. Monitoring for hepatoxicity is
recommended.
● Immune
reconstitution syndrome has been reported in patients treated with
combination antiretroviral therapy.
Adverse
reactions
The
most common adverse reactions of moderate to severe intensity and
incidence at least 2% (in those receiving TIVICAY in any one adult
trial) are insomnia, fatigue, and headache.
Drug
interactions
● Refer
to the full prescribing information for important drug interactions
with TIVICAY.
● Drugs
that are metabolic inducers may decrease the plasma concentrations
of dolutegravir.
● TIVICAY
should be taken 2 hours before or 6 hours after taking
cation-containing antacids or laxatives, sucralfate, oral
supplements containing iron or calcium, or buffered medications.
Alternatively, TIVICAY and supplements containing calcium or iron
can be taken together with food.
Use in
specific populations
●
Pregnancy: TIVICAY should be used during pregnancy only if the
potential benefit justifies the potential risk.
●
Lactation: Breastfeeding is not recommended.
Full US
prescribing information including is available at:
https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF
For the
EU Summary of Product Characteristics, please visit:
https://www.medicines.org.uk/emc/medicine/28545
About
Epivir® (lamivudine)
Lamivudine
is a nucleoside analogue used in combination with other
antiretroviral agents for the treatment of HIV infection.
Lamivudine is available in branded (Epivir) and generic forms.
Trademarks are owned by or licensed to the ViiV Healthcare group of
companies.
EPIVIR
300mg TABLETS
Professional
Indication(s) and Important Safety Information
U.S.
Indications and Usage
EPIVIR
is a nucleoside analogue reverse transcriptase inhibitor indicated
in combination with other antiretroviral agents for the treatment
of HIV-1 infection. Limitations of Use: The dosage of this
product is for HIV-1 and not HBV.
Important
safety information (ISI): Epivir (lamivudine) tablets
The
following ISI is based on the Highlights section of the Prescribing
Information for Epivir. Please consult the full Prescribing
Information for all the labelled safety information for
Epivir.
Warning:
Exacerbations of Hepatitis B, and different formulations of
Epivir
See
full prescribing information for complete boxed
warning.
● Severe
acute exacerbations of hepatitis B have been reported in patients
who are co-infected with hepatitis B virus (HBV) and human
immunodeficiency virus (HIV-1) and have discontinued EPIVIR.
Monitor hepatic function closely in these patients and, if
appropriate, initiate anti-hepatitis B treatment.
● Patients
with HIV-1 infection should receive only dosage forms of EPIVIR
appropriate for treatment of HIV-1.
Contraindications
●
EPIVIR is contraindicated in patients with previous
hypersensitivity reaction to lamivudine.
Warnings
and precautions
● Co-infected
HIV-1/HBV Patients: Emergence of lamivudine-resistant HBV variants
associated with lamivudine-containing antiretroviral regimens has
been reported.
● Lactic
acidosis and severe hepatomegaly with steatosis, including fatal
cases, have been reported with the use of nucleoside
analogues.
● Hepatic
decompensation, some fatal, has occurred in HIV-1/HCV co-infected
patients receiving interferon and ribavirin-based regimens. Monitor
for treatment-associated toxicities. Discontinue EPIVIR as
medically appropriate and consider dose reduction or
discontinuation of interferon alfa, ribavirin, or
both.
● Pancreatitis:
Use with caution in pediatric patients with a history of
pancreatitis or other significant risk factors for pancreatitis.
Discontinue treatment as clinically appropriate. (5.4)
● Immune
reconstitution syndrome has been reported in patients treated with
combination antiretroviral therapy.
● Lower
virologic suppression rates and increased risk of viral resistance
were observed in pediatric subjects who received EPIVIR oral
solution concomitantly with other antiretroviral oral solutions
compared with those who received tablets. An all-tablet regimen
should be used when possible.
Adverse
reactions
● The
most common reported adverse reactions (incidence greater than or
equal to 15%) in adults were headache, nausea, malaise and fatigue,
nasal signs and symptoms, diarrhea, and cough.
● The
most common reported adverse reactions (incidence greater than or
equal to 15%) in pediatric subjects were fever and
cough.
Drug
interactions
● Sorbitol:
Coadministration of lamivudine and sorbitol may decrease lamivudine
concentrations; when possible, avoid chronic
coadministration.
Use in
specific populations
● Lactation:
Women infected with HIV should be instructed not to breastfeed due
to potential for HIV transmission.
Full US
prescribing information including is available at:
https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF
For the
EU Summary of Product Characteristics, please visit:
https://www.medicines.org.uk/emc/product/943
About ViiV Healthcare
ViiV
Healthcare is a global specialist HIV company established in
November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE)
dedicated to delivering advances in treatment and care for people
living with HIV and for people who are at risk of becoming infected
with HIV. Shionogi joined as a shareholder in October 2012. The
company's aim is to take a deeper and broader interest in HIV/AIDS
than any company has done before and take a new approach to deliver
effective and innovative medicines for HIV treatment and
prevention, as well as support communities affected by
HIV.
For
more information on the company, its management, portfolio,
pipeline, and commitment, please visit www.viivhealthcare.com.
Cautionary
statement regarding forward-looking statements
ViiV
Healthcare Limited, the global specialist HIV company, is majority
owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi
Limited. GSK cautions investors that any forward-looking statements
or projections made by GSK, including those made in this
announcement, are subject to risks and uncertainties that may cause
actual results to differ materially from those projected. Such
factors include, but are not limited to, those described under Item
3.D 'Principal risks and uncertainties' in the company's Annual
Report on Form 20-F for 2017.
About
GSK
GSK -
one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
ViiV
Healthcare Media enquiries:
|
Melinda
Stubbee
|
+1 919
491 0831
|
|
|
|
GSK
Global Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
|
Sarah
Spencer
|
+1 215
751 3335
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
|
Danielle
Smith
James
Dodwell
|
+44 (0)
20 8047 0932
+44 (0)
20 8047 2406
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
|
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
24, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|